INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›science›PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis
science

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis

By Info60 US Desk•Summary of reporting by Financialcontent•14h ago•0 views•
Companies to use AI-enabled digital pathology and spatial single-fiber analysis to characterize the mechanistic effects of MTX-474 in systemic sclerosis
ONLY AVAILABLE IN PAID PLANS
Read Full Article

Share this story

Report an error

Up next

Related Stories

Why this robot burns the tips off cotton plants with a Laser

Why this robot burns the tips off cotton plants with a Laser

Interesting Engineering

Clark Atlanta Lands Nearly $10M Pentagon Grant to Grow AI Research

Clark Atlanta Lands Nearly $10M Pentagon Grant to Grow AI Research

Hoodline

NASA Studies Ancient Scottish Rocks To Unlock Mars’ Lost Past

NASA Studies Ancient Scottish Rocks To Unlock Mars’ Lost Past

The Daily Galaxy

AI predicts pancreatic cancer years before diagnosis

AI predicts pancreatic cancer years before diagnosis

Earth.com

Deployable Energy to test its nuclear battery at INL's DOME

Deployable Energy to test its nuclear battery at INL's DOME

Postregister

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!